RELEVENT ABSTRACTS

- Snow A.D. and Kisilevsky R. Temporal relationship between glycosaminoglycan accumulation and amyloid deposition during experimental amyloidosis. Laboratory Investigation 50: 55A, 1984 (Poster presentation at the 73rd International Academy of Pathology Meeting, San Francisco, California, March1984 and at Medical Research Day, University of Toronto, Toronto, Ontario, May 1984).

- Snow A.D., Rae G., Giles A.R. and Kisilevsky R. Serum and tissue GAG changes during experimental amyloidosis. Do they play a role in factor X metabolism ? Thrombosis and Hemostasis 54: 33, 1985. Poster presentation at the 10th International Congress on Thrombosis and Hemostasis, San Diego, California, July 1985.

- Snow A.D., Kisilevsky R. and Willmer J. Sulphated glycosaminoglycans, a common constituent of all amyloids: It's potential significance. Oral presentation at the 27th Annual National Student Research Forum, Galveston, Texas, April 1986.Winner of the Edwards S. Reynolds Award and the Mead Johnson Overall Excellence of Research Award.

- Snow A.D. and Kisilevsky R. Plasma and splenic glycosaminoglycans during experimental amyloidosis and acute inflammation. Poster presentation at the 70th Annual Meeting of the American Association of Pathologists, St. Louis, Missouri, April 1986.

- Willmer J.P., Snow A.D. and Kisilevsky R. The demonstration of sulphated glycosaminoglycans (GAGs) in association with the amyloidotic lesions of Alzheimer's disease. J Neuropath Exp Neur 45: 340, 1986. Poster presentation at the 62nd Annual Meeting of the American Association of Neuropathologists, Minneapolis, Minnesota, June 1986.

- Kisilevsky R., Snow A.D. and Willmer J.P. Was Virchow right once more? Is amyloid truly carbohydrate? Poster presentation given at the Canadian Congress of Laboratory Medicine, Kingston, Ontario, Canada, June 1986.

- Willmer J.P., Snow A.D. and Kisilevsky R. Sulphated glycosaminoglycans (GAGs) in association with neurofibrillary tangles and other filamentous inclusions. Oral presentation given at the Xth International Congress of Neuropathology, Stockholm, Sweden, Sept. 1986.

- Kisilevsky R., Snow A.D., Subrahmanyan L., Boudreau L. and Tan R. What factors are necessary for the induction of AA amyloidosis? Oral presentation given at the International Course on Amyloidosis, Gronigen, The Netherlands, Oct. 1986

- Snow A.D. and Kisilevsky R. An intimate ultrastructural association between sulphated proteoglycans and AA amyloid fibrils. Lab. Invest. 56:75A, 1987. Oral presentation given at the 76th International Academy of Pathology Meeting, Chicago, Illinois, March 1987.

- Snow A.D., Willmer J., Kisilevsky R., DeArmond S. and Prusiner S. Sulfated glycosaminoglycans (GAGs) are present in the amyloid plaques of Alzheimer's, kuru, Creutzfeldt-Jakob, Gerstmann-Straussler and experimental scrapie. Fed Proc 46 (4), 1321, 1987

RELEVENT ABSTRACTS - continued

Poster presentation at the 71st meeting of the American Association of Pathologists, Washington, D.C., April, 1987.

- Snow A.D., Kisilevsky R. and Wight T.N. Immunolocalization of heparan sulfate proteoglycans to AA amyloid deposition sites in spleen during experimental amyloidosis Oral presentation given at the Vth International Symposium on Amyloidosis, Hakone, Japan, Oct. 1987.

- Snow A.D., Mar H., Nochlin D. and Wight T.N. Corpora amylacea in aging and Alzheimer's brain contains antigenic sites for chondroitin sulfate and heparan sulfate proteoglycans. Oral presentation given at the Vth International Symposium on Amyloidosis, Hakone, Japan, Oct. 1987.

- Nochlin D., Sumi S.M., Bird T.D., Snow A.D., Masters C.L., and Beyreuther K. Familial dementia with unusual "senile" plaques with multiple amyloid cores positive for prion protein. Neurology 38 (3):266, 1988. Oral presentation given at the 40th Annual Meeting of the American Academy of Neurology, Cincinnati, Ohio, April 1988.

- Snow A.D., Nochlin D., Lara S. and Wight T.N. Cationic dyes reveal proteoglycans to be structurally integrated within the amyloidotic lesions of Alzheimer's disease. Neurology 38 (3): 266, 1988. Oral presentation given at the 40th Annual Meeting of the American Academy of Neurology, Cincinnati, Ohio, April 1988.

- Snow A.D., Mar H., Nochlin D. and Wight T.N. Ultrastructural immunolocalization of heparan sulfate proteoglycans to amyloid fibrils in the neuritic plaques of Alzheimer's disease. J Neuropath Exp Neurol 47:355, 1988. Oral presentation given at the Meeting of the American Association of Neuropathologists, Charleston, South Carolina, June 1988.

- Snow A.D., Mar H., Nochlin D. and Wight T.N. Congo red staining on 1 micron de-plasticized sections for detection of lesions in Alzheimer's disease and related disorders. Alzheimer disease and Associated Disorders 2:235, 1988. Poster presentation given at the First International Conference on Alzheimer's Disease and Related Disorders, Las Vegas, Nevada, Sept. 1988.

- Snow A.D., Nochlin D., Sumi S.M., Bird T.D. and Wight T.N. Immunolocalization of heparan sulfate proteoglycans to "primitive plaques" and multi-core prion positive plaques in familial dementia. Alzheimer Disease and Associated Disorders 2:232, 1988. Poster presentation given at the First International Conference on Alzheimer's Disease and Related Disorders, Las Vegas, Nevada, Sept. 1988.

- Snow A.D., Raskind M. and Wight T.N. The potential significance for the presence of glycosaminoglycans in the cerebrospinal fluid of normal aged and Alzheimer patients. Alzheimer disease and Associated Disorders 2:182, 1988. Oral presentation given at the First International Conference on Alzheimer's Disease and Related Disorders, Las Vegas, Nevada, Sept. 1988.

RELEVENT ABSTRACTS - continued

- Snow A.D., Mar H., Kisilevsky R., Hassell J.R. and Wight T.N. Ultrastructural immunolocalization of heparan sulfate proteoglycans to AA amyloid fibrils in spleen and liver during experimental amyloidosis. Poster presentation given at the Joint Meeting of the American Society for Cell Biology and the American Society for Biochemistry and Molecular Biology, San Francisco, CA, Jan. 1989.

- Snow A.D. and Wight T.N. Proteoglycans/ glycosaminoglycans in the pathogenesis of Alzheimer's disease and other amyloidoses. Neurobiol. Aging 11:85-86, 1990. Oral presentation given at the American Health Assistance Foundation's 15th Anniversary Conference on Alzheimer's Disease Research, Tuscon, Arizona, Feb.1989.

- Guiroy D.C., Snow A.D., Gajdusek D.C., Yanagihara R. and Garrutto R.M.Sulfated glycosaminoglycans in amyotrophic lateral sclerosis and Parkinsonism-dementia of Guam, Alzheimer's disease, Down's syndrome and Creutzfeldt-Jakob disease. UCLA Symposium, Molecular Biology of Aging, Santa Fe, New Mexico, March 1989.

- Snow A.D., Nochlin D., DeArmond S.J., Prusiner S.B., Bird T.D., Sumi S.M. and Wight T.N. Identification and localization of heparan sulfate proteoglycans in PrP amyloid plaques in Gerstmann-Straussler syndrome, Creutzfeldt-Jakob disease and scrapie.Alz Dis Assoc Dis 3:Suppl 1, 40, 1989. Oral presentation at the Second International Symposium on Familial Alzheimer's Disease, Seattle, WA, May 1989.

- Snow A.D., Kinsella M.G., Prather P.B., Nochlin D., Podlisny M.B., Selkoe D.J., Kisilevsky R. and Wight T.N. A characteristic binding affinity between heparan sulfate proteoglycans and the A4 amyloid protein of Alzheimer's disease. J Neuropath Exp Neurol 48:352, 1989. Oral presentation at the American Association of Neuropathologists Meeting, Dallas, Texas, June 1989. Honorable mention for the Weil Award.

- Snow A.D. The possible involvement of specific proteoglycans in the pathogenesis of Alzheimer's disease and other amyloidoses. Oral presentation at the 13th International Symposium on Brain Sciences, La Jolla, CA, Feb. 1990.

- Snow A.D., Mar H., Nochlin D., Sekiguchi R.T., Kimata K., Koike Y., and Wight T.N. Early accumulation of heparan sulfate in neurons and in the beta-amyloid protein containing lesions of Alzheimer's disease and Down's syndrome. Oral presentation at the 2nd International Conference on Alzheimer's Disease and Related Disorders, Toronto, Canada, July 1990.

- Snow A.D., Mar H., Nochlin D., Sekiguchi R., Kimata R., Koike Y and Wight T.N. Heparan sulfate accumulation in the beta-amyloid protein containing lesions of Alzheimer's disease and Down's syndrome is an early event. Poster presentation at the VIth International Symposium on Amyloidosis, Oslo, Norway, Aug. 1990.

RELEVENT ABSTRACTS - continued

- Snow A.D., Mar H., Nochlin D., Kresse H. and Wight T.N. Peripheral distribution of dermatan sulfate proteoglycans in amyloid-containing plaques and their presence in the neurofibrillary tangles of Alzheimer's disease. Poster presentation at the VIth International Symposium on Amyloidosis, Oslo, Norway, Aug. 1990.

- Snow A.D., Kinsella M.G., Sekiguchi R.T., Parks E. and Wight T.N. Binding by a high molecular weight heparan sulfate proteoglycan to the beta-amyloid protein of Alzheimer's disease. Oral presentation at the Western Connective Tissue Society Meeting, Ka-nee-ta, Oregon, May 1991.

- Snow A.D., Kinsella M.G., Sekiguchi R.T., Nochlin D. and Wight T.N. Binding by a high molecular weight heparan sulfate proteoglycan to the extracellular domain of the beta-amyloid protein of Alzheimer's disease. Oral presentation at the 21st Annual Meeting Society For Neuroscience, New Orleans, Louisiana, Nov. 1991.

- Snow A.D. Specific proteoglycans in the pathogenesis of Alzheimer's disease. Oral presentation at the14th Forum: Carbohydrates Coming of Age, Tokyo, Japan, May 1992

- Snow A.D., Sekiguchi R.T., Nochlin D., Kimata K., Schreier W.A. and Morgan D.G. Brain amyloid accumulation in rats within 1 week of continuous infusion of beta-amyloid protein (1-40) and an amyloid plaque co-component. Oral presentation at the 3rd International Conference on Alzheimer's Disease and Related Disorders, Padova, Italy, July 1992. Neurobiol Aging 13 (1), p. S101, 1992.

- Snow A.D., Sekiguchi R.T., Nochlin D., Kimata K., Schreier W.A. and Morgan D.G. A rat model to study the effects of BAP-containing amyloid in brain. Oral presentation at the 22nd Annual Meeting Society for Neuroscience, Anaheim, CA, Oct. 1992. Soc. Neurosc. Abstracts, v. 18 (part 2), p.1465,1992.

- Snow A.D., Sekiguchi R.T., Nochlin D., Kimata K., Schreier W.A. and Morgan D.G. Deposition of congophilic and fibrillar ß/A4 amyloid in rat brain: A critical role of heparan sulfate proteoglycans. Poster presentation at the 82nd Annual Meeting of the United States and Canadian Academy of Pathology, New Orleans, Mar. 1993. Lab Invest 68:121A, 1993

- Snow A.D., Sekiguchi R.T., Nochlin D., Schreier W.A. and Morgan D.G. An animal model to study the effects of fibrillar ß/A4 amyloid in brain. 1993 Pacific Northwest Alzheimer Disease Research Symposium, Vancouver, B.C., Canada, May 1993.

- Snow A.D., Sekiguchi R.T., Nochlin D., Schreier W.A. and Morgan D.G. An animal model to study the effects of fibrillar ß/A4 amyloid in brain. Annual Meeting of the American Association of Neuropathologists, Salt Lake City, Utah, June 1993. J. Neuropath. Exp. Neurol. 52:286, 1993.

RELEVENT ABSTRACTS - continued

- Snow A.D., Sekiguchi R.T., Potter-Perigo S., Braun K., Miller J., Ngo C. and Wight T.N. Increased expression of perlecan (heparan sulfate proteoglycan) and amyloid precursor protein during neuronal differentiation in murine embryonal carcinoma cells (P19). 23rd Annual Meeting Society for Neuroscience, Washington, D.C., Nov.1993. Soc. Neurosc. Abst. 19:623, 1993.

- Fraser P.E., McLachlan D.R., Nguyen J.T., Mizzen C.A., Snow A.D., Surewicz W.T. and Kirschner D.A. Conformation and fibrillogenesis of Alzheimer Aß peptides with selected substitution of charged residues. Fourth International Conference on Alzheimer's Disease and Related Disorders, Minneapolis, MN, July 1994

- Snow A.D., Sekiguchi R.T., Miller J., Ngo C., Wight T.N. and Kinsella M.G. Differential affinity binding of vascular cell proteoglycans to the Aß of Alzheimer's disease. Poster presentation at the Fourth International Conference on Alzheimer's Disease and Related Disorders, Minneapolis, MN, July 1994.

- Snow A.D., Kinsella M.G., Sekiguchi R.T., and Wight T.N. Vascular cell derived proteoglycans bind with differential affinities to Aß of Alzheimer's disease. Poster presentation at the XII International Congress of Neuropathology, Toronto, Ontario, Canada, Sept. 1994. Brain Pathology 4:545, 1994.

- Snow A.D., Nochlin D., Miller J., Ngo C., Gordan M., Holcomb L., and Morgan, D.G. Infusion of Aß (1-40) plus perlecan into rat brain:further studies confirming a consistent animal model to study the consequences of fibrillar Aß persistence in vivo. Oral presentation at the 24th Annual Meeting of the Society for Neuroscience, Miami Beach, Florida, Nov. 1994.

- Snow A.D. Apolipoproteins and chaperons in Alzheimer's: promiscuous or innocent escorts? Oral presentation at the 28th Annual Winter Brain Conference on Brain Research in Steamboat Springs, Colorado, Jan. 1995.

- Snow A.D., Nochlin D., Sekiguchi R., and Carlson S.S. Identification and immunolocalization of a new class of proteoglycan (keratan sulfate) to the neuritic plaques of Alzheimer's disease. Oral presentation at the Annual Meeting of the American Association of Neuropathologists, San Antonio, Texas, June 1995. J. Neuropath. Exp. Neurol. 54:436, 1995.

- Snow A.D., Cummings J.A., Ngo C.T., Yang W., Nochlin D., Rimvall K., Sheardown M.J., and Judge M. Further studies implicating the importance of perlecan (a specific heparan sulfate proteoglycan) in an animal model of fibrillar Aß amyloid deposition in vivo: comparison of Aß (1-42) versus Aß (1-40). Oral Presentation at the 25th Annual Meeting of the Society for Neuroscience, San Diego, CA, Nov. 1995. Soc. Neurosc. Abst. 21:1282, 1995.

- Maresh G.A., Nochlin D., and Snow A.D. Perlecan mRNA levels in control and Alzheimer's disease brain using reverse transcription-polymerase chain reaction (RT-PCR). Poster presentation at the 25th Annual Meeting of the Society for Neuroscience, San Diego, CA, Nov.

RELEVENT ABSTRACTS - continued

1995. Soc. Neurosc. Abst. 21:205, 1995.

- Castillo G.M., Miller J.D., Cummings J.A., Ngo C., Yang W., and Snow A.D. Purification and detailed characterization of perlecan isolated from the Engelbreth-Holm-Swarm (EHS) tumor for use in an animal model of Aß amyloid persistence in brain. Poster presentation at the 25th Annual Meeting of the Society for Neuroscience, San Diego, CA Nov. 1995. Soc. Neurosc. Abst. 21:673.15, 1995.

- Fukuchi K., Ohman T., Snow A.D., LeBoeuf R.C., Furlong C.E., and Hassell, J.R. Effects of apolipoprotein E and perlecan on aggregation and toxicity of ß-amyloid protein expressed in cultured cells. Oral Presentation at the 25th Annual Meeting of the Society for Neuroscience, San Diego, CA Nov. 1995. Soc. Neurosc. Abst. 21:1282, 1995.

- Snow A.D., Cummings J., Ngo C., Kimata K., Wight T.N., and Miller J.D.Localization of perlecan (or an immunologically related proteoglycan) to isolated microglia in vitro and to infiltrating microglia following infusion of beta-amyloid protein into rodent hippocampus. Presentation at the 5th International Conference on Alzheimer's Disease and Related Disorders, Osaka, Japan, July 1996.

- Castillo G.M. and Snow A.D. Perlecan binds to both beta-amyloid protein (Aß) 1-40 and 1-42, and is a potent accelerator and enhancer of Aß fibrillogenesis. Presentation at the 5th International Conference on Alzheimer's Disease and Related Disorders, Osaka, Japan, July 1996.

- Maresh G.A., Erezyilmaz D., Murry C.E., Nochlin D., and Snow A.D. Alterations in perlecan metabolism (decreased degradation) may be occurring in late stage Alzheimer's disease. Presentation at the 5th International Conference on Alzheimer's Disease and Related Disorders, Osaka, Japan, July 1996.

- Fukuchi K., Tokunaga T., Castillo G. M., Ngo C., Hassell J.R., and Snow A.D. Successful overexpression of the entire perlecan core protein (domains I-V) in COS cells for the ultimate development of perlecan transgenic mice. Presentation at the 5th International Conference on Alzheimer's Disease and Related Disorders, Osaka, Japan, July 1996.

- Castillo G.M., Ngo C., and Snow A.D. Perlecan binding to Alzheimer’s disease beta- amyloid protein (Aß) 1-40 regardless of the extent of fibrillogenesis. Presentation at the 26th Annual Meeting Society for Neuroscience, Washington, D.C. Soc. Neurosc. Abst. 22:1172, 1996.

- Snow A.D., Castillo G.M., Cummings J., Ngo C., and Maresh G. Further evidence implicating perlecan and other heparan sulfate proteoglycans in the pathogenesis of Alzheimer’s disease and other amyloidoses. Oral presentation at the joint meeting of the International Society for Neurochemistry and the American Society for Neurochemistry, Boston, MA, July 1997.

RELEVENT ABSTRACTS - continued

- Miller J.D., Cummings J.A., Ngo C., Kimata K., Wight T.N., and Snow A.D. Immunolocalization of perlecan to microglia in vitro and in vivo. Presentation at the 26th Annual Meeting Society for Neuroscience, Washington, D.C., Nov. 1996.

- Snow A.D., Castillo G.M., Cummings J.A., Nochlin D., Yang W., Rimvall K., Sheardown M.J., and Judge M.E. A peptide to the perlecan binding domain of the beta-amyloid protein (Aß) is a potent inhibitor of Aß-perlecan binding and Aß fibrillogenesis in vitro and in vivo. Presentation at the 26th Annual Meeting Society for Neuroscience, Washington, D.C., Nov.1996.

- Fukuchi K., Tokunaga T., Hassell J.R., and Snow A.D. Overexpression of perlecan and beta amyloid protein in transgenic mice. Presentation at the 26th Annual Meeting Society for Neuroscience, Washington, D.C., Nov.1996.

- Verchere C.B., D'Alessio D.A., Palmiter R.D., Baskin D.G., Snow A.D., Bonner-Weir S., and Kahn S.E. Characterization of islet amyloid in a transgenic mouse model of NIDDM. AFCR Regional Meeting, San Diego, CA, Nov. 1996.

- Snow A.D., Castillo G.M., Cummings J., Ngo C., and Maresh G. Further evidence implicating perlecan and other heparan sulfate proteoglycans in the pathogenesis of Alzheimer's disease and other amyloidoses. Oral presentation at the joint meeting of the International Society for Neurochemistry and the American Society for Neurochemistry, Boston, MA, July 1997.

- Snow A.D., Castillo G.M., Yang E., Ngo C., Hassell J.R., Tokunaga T., Hart M., and Fukuchi K. Overexpression of both perlecan and beta-amyloid precursor protein in P19 cells leads to a marked accumulation of beta-amyloid protein: new insights involving perlecan in Alzheimer's disease amyloidosis. XIII International Congress of Neuropathology, Perth, Australia, Sept 1997.

- Castillo G.M., Lukito W., Ngo C., and Snow A.D. The glycosaminoglycans of perlecan bind beta-amyloid protein (Aß) and enhance Aß fibril formation in a sulfate content dependent manner. XIII International Congress of Neuropathology, Perth, Australia, Sept 1997.

- Maresh G.A., Mueller C., Jin L.-W. and Snow A.D. Identification of a perlecan domain I (exon 5) splice variant specifically immunolocalized to the neurofibrillary tangles of Alzheimer's disease. Presentation at the 27th Annual Meeting for Neuroscience, New Orleans, Louisiana, Oct 25-30,1997.

- Castillo G.M., Lukito W., Peskind E., Raskind M.and Snow A.D. Laminin is a potent inhibitor of Aß fibril formation and is an Aß-binding protein present in human blood and cerebrospinal fluid. Presentation at the 27th Annual Meeting for Neuroscience, New Orleans, Louisiana, Oct 25-30, 1997.

- Lindsey D.P., Smith A., Hassell J.R., Snow A.D. and Fukuchi K. Transgenic mouse and cell culture models to study roles of perlecan (a specific heparan sulfate proteoglycan) in

RELEVENT ABSTRACTS - continued

Alzheimer's disease. Presentation at the 27th Annual Meeting for Neuroscience, New Orleans, Louisiana, Oct 25-30, 1997.

- Castillo G.M., Lukito W., Nochlin D., Ngo C. and Snow A.D. The glycosaminoglycans of perlecan bind beta-amyloid protein (Aß) and enhance Aß fibril formation in a sulfate content dependent manner. Presentation at the 27th Annual Meeting for Neuroscience, New Orleans, Louisiana, Oct 25-30, 1997.

- Maresh G.A., Mueller C., Castillo G.M. and Snow A.D. Perlecan domain I splice variants in the pathogenesis of amyloid plaque and neurofibrillary tangle formation in Alzheimer's disease. Presentation at the 6th International Conference on Alzheimer's Disease and Related Disorders, Amsterdam, July 18-23, 1998.

- Castillo G.M., Nochlin D., Wight T.N., Perry G., DeWitt D. and Snow A.D. Characterization of proteoglycans present in human Alzheimer's disease brain and in isolated amyloid plaque cores. Presentation at the 6th International Conference on Alzheimer's Disease and Related Disorders, Amsterdam, July 18-23, 1998.

- Cummings J., Castillo G.M., Ngo C., Judge M.E., Sheardown M.J., Rimvall K. and Snow A.D. Artificial amyloid plaque core deposition into rodent hippocampus: A new animal model to study amyloid plaque persistence in vivo. Presentation at the 6th International Conference on Alzheimer's Disease and Related Disorders, Amsterdam, July 18-23, 1998.

- Lukito W., Castillo G.M., Peskind E., Raskind M. and Snow A.D. Laminin and laminin fragments in human blood and cerebrospinal fluid bind Aß and maintain Aß solubility. Presentation at the 6th International Conference on Alzheimer's Disease and Related Disorders, Amsterdam, July 18-23, 1998.

- Snow A.D., Mueller C., Castillo G.M. and Maresh G.A. Specific perlecan splice variants are immunolocalized to the amyloid plaques and neurofibrillary tangles of Alzheimer's disease. Presentation at the VIII International Symposium on Amyloidosis, Rochester, MN, August 7-11, 1998.

- Snow A.D., Lukito W. and Castillo G.M. The sulfate moieties of glycosaminoglycans are critical for the enhancement of beta-amyloid protein fibril formation. Presentation at the VIII International Symposium on Amyloidosis, Rochester, MN, August 7-11, 1998.

- Snow A.D., Castillo G.M., Ngo C., Judge M.E., Sheardown M.J., Rimvall K. and Cummings J. A new animal model to study amyloid plaque persistence in vivo. Presentation at the VIII International Symposium on Amyloidosis, Rochester, MN, August 7-11, 1998.

- Castillo G.M., Lukito W., Peskind E., Raskind R. and Snow A.D. Human blood and cerebrospinal fluid contain laminin fragments which bind Aß and maintain Aß solubility.

RELEVENT ABSTRACTS - continued

- Presentation at the VIII International Symposium on Amyloidosis, Rochester, MN, August 7-11, 1998.

- Castillo G.M., Nochlin D., Wight T.N., Perry G., DeWitt D. and Snow A.D. Changes in distribution of specific classes of proteoglycans in human Alzheimer's disease brain. Presentation at the VIII International Symposium on Amyloidosis, Rochester, MN, August 7-11, 1998.

- Castillo G.M., Cummings J., Yang W., Judge M.E., Sheardown M.J., Rimvall K., Hansen J.B. and Snow A.D. The sulfate content and specific glycosaminoglycan backbone of perlecan are critical for perlecan's enhancement of islet amyloid polypeptide (amylin) fibril formation. Presentation at the VIII International Symposium on Amyloidosis, Rochester, MN, August 7-11, 1998.

- Verchere C.B., Andrikopoulos S., D'Alessio D.A., O'Brien K.D., Wight T.N., Snow A.D., Olin K.L., Chait A. and Kahn S.E. Role of apolipoprotein E and perlecan in islet amyloid formation in transgenic mice expressing human islet amyloid polypeptide. Presentation at the VIII International Symposium on Amyloidosis, Rochester, Minnesota, Aug 7-11, 1998.

- Snow A.D., Castillo G.M., Cummings J.A., Vrablic A.S. and DeSantis D.A. NeurosharpTM: A new dietary supplement containing PTI-00703 for the prevention and treatment of brain amyloidosis associated with Alzheimer's disease and aging. Presentation at Experimental Biology '99, Washington, D.C., April 1999.

- Snow A.D., Cummings J.A., Castillo G.M., Vrablic A.S. and DeSantis D.A. Further efficacy of PTI-00703: A dietary supplement which causes a dose-dependent inhibition of Alzheimer's disease amyloid deposition in a rodent model. Presentation at Experimental Biology '99, Washington, D.C., April 1999.

- Snow A.D., Castillo G.M. and Cummings J.A. Perlecan and other heparan sulfate proteoglycans in the pathogenesis of Alzheimer's disease. Oral presentation at the 15th National Meeting of the British Neuroscience Association. Yorkshire, England, April 1999.

- Snow A.D., Ngo C., Cummings J.A., Wight T.N., Lara S., Perry G., DeWitt D. and Castillo G.M. Perlecan and highly sulfated glycosaminoglycans induce spontaneous formation of Alzheimer's amyloid plaques *in vitro*. Oral presentation at the 29th Annual Meeting Society for Neuroscience, Miami, Florida, Oct 23-28, 1999.

- Cummings J.A., Castillo G.M., Lukito W., Peskind E., Raskind M. and Snow A.D. Identification of a beta-amyloid protein binding site localized to the globular domain repeats on the laminin A chain. Oral presentation at the 29th Annual Meeting Society for Neuroscience, Miami, Florida, Oct 23-28,1999.

RELEVENT ABSTRACTS - continued

- Snow A.D., Cummings J.A., Choi P.Y., Ngo C., Wight T.N., Perry G., DeWitt D., and Castillo G.M. Alzheimer's plaques re-created in a test tube: Further insights into the mechanism of amyloid plaque formation. Poster presentation at the World Alzheimer Congress 2000, Washington, D.C. July 9-13, 2000.

- Castillo G.M., and Snow A.D. The specific sulfated sugar (glucose pentasulfate) is a potent inhibitor of beta-amyloid protein fibrillogenesis. Presentation at the 30th Annual Meeting Society for Neuroscience, New Orleans, LO, Nov 4-9, 2000. Soc. Neurosc. Abstr. 26:299.4, 2000.

- Snow A.D., Choi P.Y., Cummings J.A., Wood S., Kirschner D.A., and Castillo G.M. Isolation and testing of the amyloid-inhibiting ingredients derived from the natural beta-amyloid protein fibrillogenesis inhibitor PTI-00703TM. Presentation at the 30th Annual Meeting Society for Neuroscience, New Orleans, LO, Nov 4-9, 2000. Soc. Neurosc. Abst. 26: 299.3, 2000.

- Cummings J.A., Snow A.D., Castillo G.M., Choi P.Y., and van Kuppevelt T.H. Phage display generated heparan sulfate (HS) antibodies identify specific HS epitopes within the characteristic lesions of Alzheimer's disease. Presentation at the 30th Annual Meeting Society for Neuroscience, New Orleans, LO, Nov 4-9, 2000. Soc. Neurosc. Abst. 26:201.1, 2000.

- Castillo G.M., Choi P.Y., Cummings J.A., and Snow A.D. Sulfated glycosaminoglycans and matrix molecules in the pathogenesis and treatment of amyloidosis in Alzheimer's disease. IXth International Symposium on Amyloidosis, Budapest, Hungary, July 2001. Amyloid: J. Protein Folding Disorders 8 (2) 188, 2001.

- Snow A.D., Choi P.Y., Cummings J.A., Kirschner D.A., Yee A.G., Wood S., and Castillo G.M. Proteoglycans/glycosaminoglycans in the induction of Alzheimer's amyloid plaque formation and the discovery of natural anti-amyloid agents. IXth International Symposium on Amyloidosis, Budapest, Hungary, July 2001. Amyloid: J. Protein Folding Disorders 8 (2) 186, 2001.

- Snow A.D., Rockenstein E., Cummings J.A., Castillo G.M., Choi P.Y., and Masliah E. PTI-777 treatment causes a potent reduction of amyloid plaque burden in a transgenic mouse model of Alzheimer's disease. Presentation at the 31st Annual Meeting Society for Neuroscience, San Diego, CA, Nov 10-15, 2001.

- Castillo G.M., Choi P.Y., Cummings J.A., and Snow A.D. Inhibition of Parkinson's disease alpha-synuclein fibrillogenesis by PTI-777. Presentation at the 31st Annual Meeting Society for Neuroscience, San Diego, CA, Nov 10-15, 2001.

- Cummings J., Castillo G., Nguyen B., Choi P., Rockenstein E., Masliah E., Dennissen ., Jenniskens G., van Kuppevelt T., and Snow A.D. Heparan sulfate glycosaminoglycan accumulation in amyloid plaques and cerebrovascular amyloid deposits in APP

transgenic mouse models. Presentation at the 8th International Conference on Alzheimer's Disease and Related Disorders, Stockholm, Sweden, July 2002.

- Choi P.Y., Nguyen B.P., Castillo G.M., Cummings J.A., Sanders V.J., and Snow A.D. marked induction of Alzheimer's amyloid plaque formation *in vitro* by heparan sulfateglycosaminoglycans. Presentation at the 32nd Annual Meeting for Neuroscience, Orlando, FL, Nov 2002.

- Snow A.D., Nguyen B.P., Choi P.Y., Cummings J.A., Sanders V.J., and Castillo G.M. Specific proteoglycans/ glycosaminoglycans in the pathogenesis of Alzheimer's disease and related disorders. Oral presentation at the Sixth International Conference on Alzheimer's disease and Parkinson's disease, Seville, Spain, May 2003.

- Castillo G.M., Nguyen B.P., Lake T.P., Nomizu M., and Snow A.D. Screening and identification of laminin globular domain-derived peptides as disrupters of Aß fibrils. Presentation at the 33nd Annual Meeting for Neuroscience, New Orleans, LO, Nov 2003.

- Nguyen B.P., Sanders V.J., Choi P.Y., Cummings J.A., Castillo G.M., and Snow A.D. Alzheimer's amyloid plaque formation induced by sulfated glycosaminoglycans are resistant to degradation by proteases and microglia. Presentation at the 33nd Annual Meeting for Neuroscience, New Orleans, LO, Nov 2003.

- Snow A.D., Sanders V.J., Choi P.Y., Cummings C.A., Castillo G.M., and Nguyen B.P. Alzheimer's amyloid plaque formation induced by sulfated glycosaminoglycans are resistant to degradation by proteases and microglia. Oral presentation at the Xth International Symposium on Amyloid and Amyloidosis, Tours, France, April 2004.

- Castillo G.M., Nguyen B.P., Lake T. P., Sanders V.J., Nomizu M., and Snow A.D. Identification of laminin globular domain-derived peptides as disrupters of Aß fibrils. Presentation at the 9th International Conference on Alzheimer's Disease and Related Disorders, Philadelphia, PA, July 2004.

- Sanders V.J., Snow A.D., Choi P.Y., Cummings J. A., Castillo G.M., and Nguyen B.P. Alzheimer's amyloid plaque formation induced by sulfated glycosaminoglycans are resistant to degradation by proteases and microglia. Presentation at the 9th International Conference on Alzheimer's Disease and Related Disorders, Philadelphia, PA, July 2004.

- Snow A.D., Cummings J.A., Castillo G.M., Lake T.P., Choi P.Y., Sanders V.J., and Nguyen B.P. Development of Exebryl-1: A Disease Modifying Compound that Causes a Marked Clearance of Brain Amyloid Plaque Burden and Improved memory in Transgenic Mouse Models of Alzheimer's disease. Presentation at "Alzheimer's Disease:From Molecular Mechanisms to Drug Discovery", Cancun, Mexico, Dec 11-17, 2004.

RELEVENT ABSTRACTS - continued

- Snow A.D., Cummings J.A., Lake T.P., Masliah E., Rockenstein E., and Castillo G.M. Development of Novel Disease-Modifying Small Peptides that Cause a Reduction of Brain Amyoid Plaque Load and Improved Memory in a Transgenic Mouse Model of Alzheimer's Disease. Presentation at the 35th Annual Meeting of Neuroscience, Washington D.C., Nov 2005.

- Cummings J.A., Masliah E., Rockenstein E., and Snow A.D. Heparan sulfate proteoglycan accumulation occurs concurrent with Aß amyloid plaque deposition in APP transgenic mouse models of Alzheimer's disease. Presentation at the 35th Annual Meeting of Neuroscience, Washington D.C., Nov 2005.

- Snow A.D., Cummings J.A., and Lake T.P. Reduction of Brain Amyloid Load by the Small Molecule Therapeutic Exebryl-1 following Oral Treatment in a Transgenic Mouse Model of Alzheimer's Disease. Presentation at Neuroscience 2006, Atlanta, GA, Nov 2006.

- Snow A.D., Cummings J.A., Lake T.P., Esposito L.A., Rockenstein E., Masliah E., Cheng F., Ferree A., Saha S., and Wolozin B. Proteoglycans/ glycosaminoglycans in the Pathogenesis of Alzheimer's and Parkinson's Disease and the Development of Novel Small Molecule Amyloid Disease-Modifying Therapeutics. Oral Presentation at the 8th International Conference on Alzheimer's and Parkinson's Disease, Saltburg, Austria, March 2007.

- Esposito L.A., Cummings J.A., Lake T.P., Hudson F., Cheng F., Ferree A., Saha S., Wolozin B., and Snow A.D. Screening and identification of small molecule inhibitors of alpha-synuclein aggregation in A53T alpha-synuclein overexpressing cells treated with rotenone. Presentation at Neuroscience 2007, San Diego, CA, Nov 2007.

- Snow A.D., Cummings J.A., Lake T.P., Hudson F.M., Esposito L.A., Kastin A., Hsuchou H, and Pan W. Blood-brain-barrier penetration of a novel disease-modifying small peptide (DP74) that reduced brain amyloid load and improves memory in a transgenic mouse model of Alzheimer's disease. Presentation at Neuroscience 2007, San Diego, CA, Nov 2007.

- Snow A.D., Cummings J.A., Lake T.P., Esposito L.A., Hudson F.M., Hu H., Cam J.A., Aker J.R., and Runnels S. Exebryl-1: A novel small molecule drug that markedly reduces amyloid plaque load and improves memory, enters human clinical trials. Presentation at International Conference on Alzheimer's Disease, Chicago, IL, July 2008.

- Snow A.D., Cummings J.A., Lake T.P., Hudson F.M., Esposito L.A., Kastin A., Hsuchou H, and Pan W. Blood-brain-barrier penetration of a novel disease-modifying 7-mer peptide (DP-74) that reduces brain amyloid load and improves memory in a transgenic mouse model of Alzheimer's disease. Presentation at International Conference on Alzheimer's Disease, Chicago, IL, July 2008.